Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer

Table 1 Univariate and multivariate survival analysis for overall survival and recurrence-free survival in The Cancer Genome Atlas patients with hepatocellular carcinoma

Variables	Overall survival		Recurrence-free survival
	Relative risk (95%CI)	P value	Relative risk (95%CI)	P value
Univariate
Age (> 60 vs ≤ 60 yr)	1.17 (0.76-1.80)	0.48	1.33 (0.83-2.14)	0.24
Gender (female vs male)	1.21 (0.78-1.86)	0.39	0.91 (0.72-1.15)	0.44
Differentiation (Poorly vs well and moderately)	1.27 (0.83-1.95)	0.28	0.76 (0.48-1.21)	0.25
Residual tumor (R1 + R2 vs R0)	1.95 (0.94-4.06)	0.07	2.25 (1.02-4.98)	0.05
Child-Pugh classification (grade B vs A)	2.49 (1.21-5.12)	0.01	2.22 (0.95-5.19)	0.07
Vascular invasion (macro + micro vs none)	1.52 (0.94-2.46)	0.08	1.65 (1.00-2.71)	0.05
TNM staging (III + IV vs I + II)	2.39 (1.51-3.79)	< 0.001	4.32 (2.50-7.47)	< 0.001
Fibrosis (fibrosis + cirrhosis vs none)	0.98 (0.88-1.08)	0.63	0.81 (0.46-1.41)	0.45
AFP (≥ 200 ng/mL vs < 200 ng/mL)	1.15 (0.68-1.92)	0.61	0.85 (0.49-1.49)	0.58
PRDX1 expression (high vs low)	1.55 (1.01-2.36)	0.04	1.01 (0.63-1.60)	0.98
Inflammation in adjacent liver (severe + mild vs none)	1.20 (0.79-1.80)	0.39	1.30 (0.82-2.07)	0.26
Multivariate
Residual tumor (R1 + R2 vs R0)	-	-	0. 89 (0.28-2.89)	0.77
Child-Pugh classification (grade B vs A)	2.30 (1.10-4.78)	0.03	-	-
Vascular invasion (macro + micro vs none)	-	-	1.42 (0.79-2.55)	0.23
TNM staging (III + IV vs I + II)	2.36 (1.26-4.41)	0.007	5.04 (2.76-9.22)	< 0.001
PRDX1 expression (high vs low)	1.89 (1.07-3.36)	0.03	-	-

AFP: α-fetoprotein; PRDX1: Peroxiredoxin 1.

Table 2 Expression of peroxiredoxin 1 protein and its clinical significance

	22 kDa band		P value	50 kDa band		P value
	n	Up-regulated (%)		n	Down-regulated (%)
Gender
Male	26	45.2 (12/26)	1.00	26	69.2 (18/26)	1.00
Female	3	33.3 (1/3)		3	66.7 (2/3)
Age
≥ 60	10	30.0 (3/10)	0.43	10	40.0 (4/10)	0.03
< 60	19	52.6 (10/19)		19	65.5 (16/19)
Tumor size
≤ 3 cm	7	42.9 (3/7)	1.00	7	42.9 (3/7)	0.16
> 3 cm	22	45.5 (10/22)		22	77.3 (17/22)
Differentiation
Well	7	28.6 (2/7)	0.41	7	71.45 (5/7)	1.00
Moderately	18	55.6 (10/18)		18	66.7 (12/18)
Poorly	4	25.0 (1/4)		4	75.0 (3/4)
TNM staging
I-II	20	35.0 (7/20)	0.23	20	70.0 (14/20)	1.00
III-IV	9	66.7 (6/9)		9	66.7 (6/9)
AFP
≥ 200 ng/mL	7	42.9 (3/7)	1.00	7	71.4 (5/7)	1.00
< 200 ng/mL	22	45.5 (10/22)		22	68.2 (15/22)

AFP: α-fetoprotein.